Intravenous immunoglobulin (IVIg)- impact of serum IgG peak-through differences for maintaining anti-inflammatory pathways in CIDP
Recruiting
- Conditions
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
- Registration Number
- DRKS00025759
- Lead Sponsor
- Grifols Deutschland GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Confirmed CIDP with sensory and/or motor deficits treated with either IVIg or SCIg. Furthermore, written informed consent is required.
Exclusion Criteria
Underaged and/or non legally-competent persons, as well as subjects not providing written informed consent for study participation are excluded from the study. Furthermore, therapy with monocloncal antibodies, corticosteroids or immunosuppressants have to be excluded.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of immune cells, their receptors and cytokines will be examined subsequent to IVIg or SCIg infusion to identify specific patterns of activation.
- Secondary Outcome Measures
Name Time Method o secondary outcome parameter defined.